Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Samuele Cazzamalli"'
Autor:
Wen Torng, Ilaria Biancofiore, Sebastian Oehler, Jin Xu, Jessica Xu, Ian Watson, Brenno Masina, Luca Prati, Nicholas Favalli, Gabriele Bassi, Dario Neri, Samuele Cazzamalli, Jianwen A. Feng
Publikováno v:
ACS Omega, Vol 8, Iss 28, Pp 25090-25100 (2023)
Externí odkaz:
https://doaj.org/article/0d6aaf5a697c4856b4e874e86c014835
Autor:
Lydia Bisbal Lopez, Domenico Ravazza, Matilde Bocci, Aureliano Zana, Lucrezia Principi, Sheila Dakhel Plaza, Andrea Galbiati, Ettore Gilardoni, Jörg Scheuermann, Dario Neri, Luca Pignataro, Cesare Gennari, Samuele Cazzamalli, Alberto Dal Corso
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Immune-stimulating antibody conjugates (ISACs) equipped with imidazoquinoline (IMD) payloads can stimulate endogenous immune cells to kill cancer cells, ultimately inducing long-lasting anticancer effects. A novel ISAC was designed, featuring the IMD
Externí odkaz:
https://doaj.org/article/b9edd8a96d8444cc849c81174ca18bed
Autor:
Baptiste Gouyou, Jacopo Millul, Alessandra Villa, Samuele Cazzamalli, Dario Neri, Mattia Matasci
Publikováno v:
ACS Omega, Vol 5, Iss 40, Pp 26077-26083 (2020)
Externí odkaz:
https://doaj.org/article/183e4995d9d949989a80097e4a6b17e9
Autor:
Francesco Bartoli, Philip Elsinga, Luiza Reali Nazario, Aureliano Zana, Andrea Galbiati, Jacopo Millul, Francesca Migliorini, Samuele Cazzamalli, Dario Neri, Riemer H. J. A. Slart, Paola Anna Erba
Publikováno v:
Pharmaceuticals, Vol 15, Iss 8, p 958 (2022)
FAP-targeted radiopharmaceuticals represent a breakthrough in cancer imaging and a viable option for therapeutic applications. OncoFAP is an ultra-high-affinity ligand of FAP with a dissociation constant of 680 pM. OncoFAP has been recently discovere
Externí odkaz:
https://doaj.org/article/9b8e960e1d47425a9a726420423c1258
Autor:
Samuele Cazzamalli, Eduard Figueras, Lilla Pethő, Adina Borbély, Christian Steinkühler, Dario Neri, Norbert Sewald
Publikováno v:
ACS Omega, Vol 3, Iss 11, Pp 14726-14731 (2018)
Externí odkaz:
https://doaj.org/article/1dbd508179914e53a63876afc1a200a8
Autor:
Sheila Dakhel, Christian Lizak, Mattia Matasci, Jacqueline Mock, Alessandra Villa, Dario Neri, Samuele Cazzamalli
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 18, p 10020 (2021)
Antibody-cytokine fusion proteins (immunocytokines) are gaining importance for cancer therapy, but those products are often limited by systemic toxicity related to the activity of the cytokine payload in circulation and in secondary lymphoid organs.
Externí odkaz:
https://doaj.org/article/a6505dcd372f407391b9d37789feb336
Publikováno v:
CHIMIA, Vol 71, Iss 10 (2017)
Cytotoxic drugs, which are commonly used for the pharmacotherapy of many forms of cancer, often cause substantial toxicity to the patient without being able to induce long-lasting remissions. Ligands specific to accessible tumor-associated targets, c
Externí odkaz:
https://doaj.org/article/33efbb17f6a24f6fb25c3db3d2879c24
Autor:
Sara Puglioli, Eleonore Schmidt, Christian Pellegrino, Luca Prati, Sebastian Oehler, Roberto De Luca, Andrea Galbiati, Claudia Comacchio, Lisa Nadal, Jörg Scheuermann, Markus G. Manz, Dario Neri, Samuele Cazzamalli, Gabriele Bassi, Nicholas Favalli
Publikováno v:
Chem. 9:411-429
Autor:
Aureliano Zana, Andrea Galbiati, Ettore Gilardoni, Matilde Bocci, Jacopo Millul, Theo Sturm, Riccardo Stucchi, Abdullah Elsayed, Lisa Nadal, Martina Cirillo, Wolfgang Roll, Lars Stegger, Inga Asmus, Philipp Backhaus, Michael Schäfers, Dario Neri, Samuele Cazzamalli
Publikováno v:
Clinical Cancer Research, 28 (24)
Purpose: Small molecule drug conjugates (SMDC) are modular anticancer prodrugs that include a tumor-targeting small organic ligand, a cleavable linker, and a potent cytotoxic agent. Most of the SMDC products that have been developed for clinical appl
Autor:
Andrea Galbiati, Aureliano Zana, Matilde Bocci, Jacopo Millul, Abdullah Elsayed, Jacqueline Mock, Dario Neri, Samuele Cazzamalli
Publikováno v:
J Nucl Med
Imaging procedures based on small-molecule radioconjugates targeting fibroblast activation protein (FAP) have recently emerged as a powerful tool for the diagnosis of a wide variety of tumors. However, the therapeutic potential of radiolabeled FAP-ta